NtRON Bio announced today, following its recent U.S. patent application related to colorectal cancer using the IMPA™ phage engineering technology, it has now completed the filing of two patents for a ...

Later pregnancies carry higher risks. Advances in genetic reproductive medicine, like IVF and NIPT, are making it possible ...

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its ...

--Genetic Technologies Limited, a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, today announced that it has entered into a definitive agreement ...

The inaugural Genetic Agency Technology Conference (GATC) on November 11th, 2025 will convene technical thought leaders, gene therapy developers, patients, their families, and patient advocates ...

--Genetic Technologies Limited, a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024 ...

Genetic Technologies and Australia-based University of Melbourne have entered a license agreement to develop a new colorectal cancer risk assessment test. Here’s what you need to know: 1. The risk ...

Buy a copy of the Dire Wolf issue here Relying on deft genetic engineering and ancient, preserved DNA, Colossal scientists deciphered the dire wolf genome, rewrote the genetic code of the common ...

Genetic engineering is considered one of the most sophisticated scientific tools for changing the genetic blueprint of a ...

The Genetic Agency Technology Conference Dyno’s GATC event is scheduled to take place in Boston, Massachusetts on November 11th, 2025.

One genetic treatment for a skin disease, approved in the US last year, is formulated as a cream— the first rub-on gene therapy (though not a gene editor).

Genetic Technologies ( (AU:GTG) ) has provided an update. Genetic Technologies Limited reported a 15% decrease in revenue for the half-year ending December 31, 2024, with a loss after tax down 36% to ...